Human test of Iranian corona vaccine until March 31
A member of the scientific team of “Kuvairan Barakat” vaccine explained the situation of the candidates in the first stage of the clinical trial and explained about the continuation of the Iranian vaccine production process.
In an interview with ISNA, Dr. Payam Tabarsi, regarding the details and steps of the Iranian Covid 19 vaccine, said that the first phase of the clinical trial of the vaccine is going well. Clinically, it will be issued and the vaccine will be given to all 56 volunteers by March 31.
He stated that the results of the work have been positive so far and the general condition of the first 21 volunteers is favorable, adding: “So far, no special and worrying complications have been reported.”
Dr. Tabarsi stated that the final results of the first phase of the clinical trial of the Kovayran vaccine will be determined about 4 weeks after the second injection and after examining the antibody titer of the volunteers. It is too early to make a final decision.
The member of the scientific team of “Kuvairan Barakat” vaccine continued: “Due to the positive steps taken so far and the favorable situation of the first 21 volunteers, the next stage will be performed more quickly until the end of the injection of 56 volunteers in the first stage of the trial.”
Dr. Tabarsi said that if the results of the first phase of the trial are successful, the second phase will begin in early April 1400, said: The second phase of the vaccine clinical trial will be performed with about 500 volunteers and the results will be determined by the end of May.
He explained that parts of the second and third phases of the clinical trial of “Kuvairan Barakat” vaccine will probably be merged.
A member of the scientific team of Koviran Iran vaccine stated that if the final results of the trial are successful, the general vaccination will start in late spring. The Iranian vaccine will start in late spring if the plan is successful and the necessary permits are obtained.